四環醫藥(00460.HK)旗下渼顏空間擬與藍晶微生物成立合資公司
格隆匯1月21日丨四環醫藥(00460.HK)發佈公吿，集團旗下北京渼顏空間科技有限公司與北京藍晶微生物科技有限公司於2022年1月19日簽署協定，雙方將成立合資公司，共同開發包括PHA微球及基於生物製造的再生醫學材料，雙方將共同完成產品的研發、合規化申報及後續商業化推廣。
根據披露，PHA是一種存在於微生物胞內的天然聚酯，由羥基脂肪酸單體中的羧基和同種或不同種羥基脂肪酸單體中的羥基形成酯鍵連接起來的線性高分子。PHA在體內與細胞具有良好的生物相容性，最終降解產物為二氧化碳和水，對細胞無毒性，細胞可以在由PHA製成的支架上良好生長，因此PHA在醫學領域具有廣泛應用。由於PHA具有特殊的生物可降解性、氣體相隔性、生物組織相容性、抗凝血性、疏水性、光學異構性等特點，在作為高端的生物醫用材料應用於醫療設備、組織工程和藥物載體等領域具有獨特的優勢。由 PHA製成的手術縫合線、可吸收手術膜等醫療器械已在美國獲FDA批准上市。
藍晶微生物成立於2016年，是一家基於合成生物技術從事分子與材料創新的企業，致力於設計、開發、製造和銷售新型生物基分子和材料，2022年1月完成累計人民幣15億元B系列融資。藍晶微生物是國內合成生物學產業化先行者之一，其擁有的合成生物學研發平台可根據使用者需求設計各種性能卓越的PHA材料，其應用場景覆蓋消費品、食品、醫療、農業和工業等眾多行業。藍晶微生物在菌株研發、生物轉化、分離純化、材料改性等PHA相關技術鏈的各個環節均有豐富的技術儲備與知識產權佈局，包括 PHA微球凍乾粉的製備工藝。
此次集團與藍晶微生物就用於醫療美容的PHA微球相關產品的技術開發和商業化應用達成戰略合作，共同成立合資公司，使得集團有機會提前入局合成生物學這個巨大的產業藍海，成功邁出從醫美產業端向上遊原料端縱向延伸的重要第一步，這將不僅協助集團進一步完善其在醫美領域的產品矩陣，同時將大幅提高集團在非手術類醫美領域的綜合實力，增強集團的核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
